Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN027 in advanced malignant solid tumors
NCT07391644Phase 1Not yet recruiting
- Sponsor
- Alphamab Oncology
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JSKN027 in advanced malignant solid tumor, sponsored by Alphamab Oncology. Primary endpoints: Number of Participants With Dose-Limiting Toxicities at 21 days, Number of Participants With Treatment-Emergent Adverse Events and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
JSKN027
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT07391644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07391644.